Stig Pedersen, executive vice president of commercial operations at Lundbeck, said: “The reimbursement of Azilect is of great importance to the many patients in France suffering from parkinson’s disease, looking for treatment options beyond symptomatic benefits. Azilect is the first and only product that has demonstrated effect on slowing clinical progression of parkinson’s Disease and we are looking forward to providing it to the French market.”
Recent data from the ADAGIO study, published in The New England Journal of Medicine in September 20091, provide evidence that early treatment with Azilect slows clinical progression of the disease. The results also support the possibility that Azilect has a disease-modifying effect.
Azilect tablets (rasagiline tablets) are indicated for the treatment of parkinson’s disease, both as initial monotherapy and as adjunct to levodopa later in the disease.
Azilect tablets are now available in 38 countries, including the US, Canada, Israel, Mexico and all of the EU countries.
As part of a long-term strategic alliance, Azilect is co-promoted by Teva and Lundbeck in key European countries, including France, and marketed by Lundbeck in other markets in Europe and outside.